Source-grounded facts extracted from WINDTREE THERAPEUTICS INC /DE/'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
WINDTREE THERAPEUTICS INC /DE/ incurred convertible notes of $857,142.86 with an institutional investor at 10% per annum maturing November 26, 2026.
“issued to an institutional investor (the “Holder”) an aggregate principal amount of $857,142.86 in senior convertible promissory notes due 2026 (the “2026 Notes”).”
WINDTREE THERAPEUTICS INC /DE/ incurred convertible notes of $1,600,000 with institutional investors at 10% per annum on a 360-day basis maturing October 9, 2026.
“On October 9, 2025, Windtree Therapeutics, Inc. (the “Company”) issued to institutional investors (collectively, “Holders” and each a “Holder”) an aggregate principal amount of $1,600,000 in senior convertible promissory notes due 2026 (the “Commitment Notes”).”
WINDTREE THERAPEUTICS INC /DE/ received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
“August 19, 2025, Windtree Therapeutics Inc. (the “ Company ” ) was notified by The Nasdaq Stock Market LLC (“ Nasdaq ”) that as a result of the Company’s previously disclosed noncompliance with Nasdaq Listing Rule 5550(a)(2), Nasdaq has determined to delist the Company’s common stock from the Nasdaq Capital Market and, accordingly, will suspend trading in the Company’s common stock effective at the open of trading on August 21, 2025. The Company expects that its common stock will begin trading publicly on the over-the-counter market on August 21, 2025, under its existing symbol “WINT.” The Com”
WINDTREE THERAPEUTICS INC /DE/ incurred convertible notes of $10,000,000 at 5% per annum maturing April 23, 2026.
“the Company issued a convertible promissory note (the “Commitment Note”) to the Purchaser in the amount of $10,000,000. The Commitment Note matures on April 23, 2026 (the “Maturity Date”) and will bear interest at 5% per annum on a 365-day basis, due and payable on the Maturity Date.”
WINDTREE THERAPEUTICS INC /DE/ received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv), 5815(4)(A)).
“June 18, 2025, Windtree Therapeutics, Inc. (the “ Company ”) received a deficiency letter (the “ Bid Price Deficiency Letter ”) from the Nasdaq Listing Qualifications Department (the “ Staff ”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (“ Minimum Bid Price Requirement ”). Normally, a company would be afforded a 180-cal”
Craig Fraser resigned as Director at WINDTREE THERAPEUTICS INC /DE/.
“On April 17, 2025, Mr. Fraser notified the Windtree Therapeutics, Inc.(the “ Company ”) Board of Directors (the “ Board ”) of his resignation from the Board, effective immediately.”
Leanne Kelly was appointed as director and chair of the Audit Committee at WINDTREE THERAPEUTICS INC /DE/.
“On January 8, 2025, the Board of Directors (the "Board") of Windtree Therapeutics, Inc. (the "Company") approved an increase in the number of directors on the Board to five and appointed Leanne Kelly as a director and member and chair of the Audit Committee, effective immediately.”
Jed Latkin was appointed as President and Chief Executive Officer at WINDTREE THERAPEUTICS INC /DE/.
“the Company announced the appointment of Jed Latkin, age 50, a current member of the Board, to serve as the Company’s President and Chief Executive Officer, effective as of the Transition Date.”
Craig Fraser retired as President and Chief Executive Officer at WINDTREE THERAPEUTICS INC /DE/.
“Craig Fraser will retire as the Company’s President and Chief Executive Officer, effective as of December 1, 2024”
Jamie McAndrew was appointed as Senior Vice President and Chief Financial Officer at WINDTREE THERAPEUTICS INC /DE/.
“On September 25, 2024, the board of directors (the “ Board ”) of Windtree Therapeutics, Inc. (the “ Company ”) appointed Jamie McAndrew as Senior Vice President and Chief Financial Officer, effective as of September 25, 2024 (the “ Effective Date ”).”
Saundra Pelletier was appointed as Director at WINDTREE THERAPEUTICS INC /DE/.
“On August 13, 2024, the Board appointed Jed Latkin and Saundra Pelletier to fill the vacancies created by the resignation of Mr. Geffken and Ms. Williams, effective August 13, 2024.”
Jed Latkin was appointed as Director at WINDTREE THERAPEUTICS INC /DE/.
“On August 13, 2024, the Board appointed Jed Latkin and Saundra Pelletier to fill the vacancies created by the resignation of Mr. Geffken and Ms. Williams, effective August 13, 2024.”
Leslie J. Williams resigned as Director at WINDTREE THERAPEUTICS INC /DE/.
“On August 13, 2024, Daniel Geffken and Leslie J. Williams each notified Windtree Therapeutics, Inc. (the “Company”) of his or her resignation from the Board of Directors of the Company (the “Board”), including all committees of the Board on which he or she serves, effective August 13, 2024.”
Daniel Geffken resigned as Director at WINDTREE THERAPEUTICS INC /DE/.
“On August 13, 2024, Daniel Geffken and Leslie J. Williams each notified Windtree Therapeutics, Inc. (the “Company”) of his or her resignation from the Board of Directors of the Company (the “Board”), including all committees of the Board on which he or she serves, effective August 13, 2024.”
WINDTREE THERAPEUTICS INC /DE/: Effected a 1-for-18 reverse stock split of common stock via amendment to the Amended and Restated Certificate of Incorporation (effective 2024-04-19).
“On April 19, 2024, the Company filed the Amendment for the Reverse Stock Split with the Secretary of State of the State of Delaware, and the Reverse Stock Split will become effective in accordance with the terms of the Amendment at 11:59 p.m. Eastern Time on April 19, 2024”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.